2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

What happened: Innovent Biologics (HKEX: 01801) presented first international Phase 1 data for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, at the 2026 ESMO Congress in a Proffered Paper session. Key numbers: 57 patients received IBI3001 monotherapy (1 mg/kg to 10 mg/kg); 78.9% had at least 2 prior treatments. Why it matters: Innovent said the data support its bispecific ADC platform and that IBI3001 has advanced to dose optimization in a Phase 1b proof-of-concept study, with plans to validate efficacy and safety in Market: +2.1% today ($83.35), +5.8% YTD, 1.3x vol — as of 07:45 UTC

Innovent Biologics (HKEX: 01801) presented first international Phase 1 data for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, at the 2026 ESMO Congress in a Proffered Paper session.

Innovent said the data support its bispecific ADC platform and that IBI3001 has advanced to dose optimization in a Phase 1b proof-of-concept study, with plans to validate efficacy and safety in Market: +2.1% today ($83.35), +5.8% YTD, 1.3x vol — as of 07:45 UTC